MARKET

CBLI

CBLI

Cytocom Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

4.240
-0.120
-2.75%
Closed 16:00 07/30 EDT
OPEN
4.350
PREV CLOSE
4.360
HIGH
4.600
LOW
4.233
VOLUME
153.59K
TURNOVER
--
52 WEEK HIGH
10.97
52 WEEK LOW
1.620
MARKET CAP
65.59M
P/E (TTM)
-23.7668
1D
5D
1M
3M
1Y
5Y
QFIN, DFH, BON among mid-day movers
Gainers: Intec Pharma (NASDAQ:NTEC) +61%. LendingClub Corporation (NYSE:LC) +55%. NanoVibronix (NASDAQ:NAOV) +36%. Golden Star Resources (NYSE:GSS) +28%. Dream Finders Homes (NASDAQ:DFH) +17%. E-Home Household Service Holdings (NASDAQ:EJH) +17%. Tempur Sea...
Seekingalpha · 1d ago
Cleveland BioLabs secures $90M in debt and equity financing
Cytocom (CBLI -11.4%) announced agreements that could potentially add $90M in committed capital to the company in the form of debt and equity. The financing includes an equity commitment of $75M
Seekingalpha · 1d ago
NanoVibronix, Intec Pharma leads healthcare gainers; Annovis Bio, Atreca among major losers
Gainers: NanoVibronix NAOV +49%, Intec Pharma (NASDAQ:NTEC) +31%, Cocrystal Pharma COCP +17%, Burning Rock Biotech (NASDAQ:BNR) +11%, Genetron (NASDAQ:GTH) +8%. Losers: Annovis Bio ANVS -48%, Atreca (NASDAQ:BCEL) -35%, Forward Pharma (NASDAQ:FWP) -21%, Cle...
Seekingalpha · 1d ago
BRIEF-Cytocom Receives Commitments For $90 Mln In Equity And Debt Financing
reuters.com · 1d ago
12 Health Care Stocks Moving In Thursday's Pre-Market Session
 
Benzinga · 1d ago
Cytocom, Inc. Receives Commitments for $90 Million in Equity and Debt Financing
/PRNewswire/ -- , (NASDAQ: CBLI), a leading biopharmaceutical company developing next generation therapies that focus on immune homeostasis, has secured agreements for in committed capital. The financing is led by a equity commitment from  in the form of...
PR Newswire - PRF · 1d ago
Cytocom Inc. Announces Completed Merger with Cleveland BioLabs
/PRNewswire/ -- Cytocom Inc. ("Cytocom" or "Company"), a leading biopharmaceutical company creating next-generation therapies that focus on immune homeostasis, today announced the completion of its merger with Cleveland BioLabs, Inc. The all-stock transact...
PR Newswire - PRF · 2d ago
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers
Benzinga · 07/15 20:34
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of CBLI. Analyze the recent business situations of Cytocom Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
EPS
Institutional Holdings
Institutions: 27
Institutional Holdings: 1.07M
% Owned: 6.90%
Shares Outstanding: 15.47M
TypeInstitutionsShares
Increased
6
279.69K
New
6
564.61K
Decreased
1
35.10K
Sold Out
5
364.46K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
-0.25%
Pharmaceuticals & Medical Research
-0.39%
Key Executives
Chairman/Independent Director
Lea Verny
President/Chief Executive Officer/Director
Michael Handley
Chief Financial Officer
Peter Aronstam
Chief Operating Officer/Director
Taunia Markvicka
Chief Technology Officer
Robert Buckheit
Vice President - Finance
Christopher Zosh
Other
Cozette Mcavoy
Other
Clifford Selsky
Director
Steve Barbarick
Independent Director
Randy Saluck
No Data
About CBLI
Cytocom, Inc., formerly Cleveland BioLabs, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing small molecule immunotherapies, which targets autoimmune, inflammatory, infectious diseases and cancers. Its advanced immunomodulating multi-receptor system (AIMS) platform is a drug discovery and development platform, which is designed to restore immune homeostasis. Its immunomodulatory drugs are developed using AIMS platform, which adjusts immune responses to halt or slow disease progression. Its clinical-stage development programs are focused on treating Crohn's disease, fibromyalgia, multiple sclerosis and pancreatic cancer. The Company’s programs include CYTO-200 AIMS Program, CYTO-400 AIMS Program and CYTO-600 Program. The company also has a platform of toll-like immune receptors (TLR4, TLR5 and TLR9), which address the conditions such as radiation sickness and cancer treatment side effects.

Webull offers kinds of Cytocom Inc stock information, including NASDAQ:CBLI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CBLI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading CBLI stock methods without spending real money on the virtual paper trading platform.